Role of immunmodulators in allergen-specific immunotherapy

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 66, Issue 6, 2011, Pages 792-797

  Kopp, M V ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

allergic rhinitis; allergy; asthma; Omalizumab; specific immunotherapy

Indexed keywords

ALLERGEN; CPG OLIGODEOXYNUCLEOTIDE; IMMUNOGLOBULIN E; IMMUNOMODULATING AGENT; OLIGODEOXYNUCLEOTIDE; OMALIZUMAB; PEPTIDOLEUKOTRIENE; PHOSPHORYL LIPID A; PLACEBO; TOLL LIKE RECEPTOR 4;

ADJUVANT THERAPY; ALLERGIC ASTHMA; ALLERGIC RHINITIS; ALLERGY; ANAPHYLAXIS; ASTHMA; B LYMPHOCYTE; BEE STING; DNA SEQUENCE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GRASS POLLEN; HAY FEVER; HUMAN; IMMUNOTHERAPY; INNATE IMMUNITY; LOWER RESPIRATORY TRACT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT ALLERGY; REVIEW; RHINITIS; UPPER RESPIRATORY TRACT;

ADOLESCENT; ADULT; ALLERGENS; ANIMALS; ANTI-ALLERGIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ASTHMA; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; DESENSITIZATION, IMMUNOLOGIC; HUMANS; MIDDLE AGED; MITES; POLLEN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RHINITIS, ALLERGIC, SEASONAL; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79955364609     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/j.1398-9995.2011.02553.x     Document Type: Review

References (32)

1. Abramson MJ, Puy RM, Weiner JM,. Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev 2010; 8: CD001186.
2. Bousquet J, Michel FB,. Safety considerations in assessing the role of immunotherapy in allergic disorders. Drug Saf 1994; 10: 5-17. (Pubitemid 24032936)
3. Bernstein DI, Wanner M, Borish L, Liss GM,. Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001. J Allergy Clin Immunol 2004; 113: 1129-1136. (Pubitemid 38857996)
4. Holgate S, Smith N, Massanari M, Jimenez P,. Effects of omalizumab on markers of inflammation in patients with allergic asthma. Allergy 2009; 64: 1728-1736.
5. Kopp MV, Brauburger J, Riedinger F, Beischer D, Ihorst G, Kamin W, et al., The effect of anti-IgE treatment on in vitro leukotriene release in children with seasonal allergic rhinitis. J Allergy Clin Immunol 2002; 110: 728-735. (Pubitemid 35423175)
6. Kopp MV, Stenglein S, Kamin W, Friedrichs F, von Berg A, Zielen S, et al., Omalizumab (Xolair) in children with seasonal allergic rhinitis: leukotriene release as a potential in vitro parameter to monitor therapeutic effects. Pediatr Allergy Immunol 2007; 18: 523-527. (Pubitemid 47206746)
7. Eckman JA, Sterba PM, Kelly D, Alexander V, Liu MC, Bochner BS, et al., Effects of omalizumab on basophil and mast cell responses using an intranasal cat allergen challenge. J Allergy Clin Immunol 2010; 125: 889-895.
8. Kuehr J, Brauburger J, Zielen S, Schauer U, Kamin W, von Berg A, et al., Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol 2002; 109: 274-280. (Pubitemid 34158294)
9. Rolinck-Werninghaus C, Hamelmann E, Keil T, Kulig M, Koetz K, Gerstner B, et al,; Omalizumab Rhinitis Study Group. The co-seasonal application of anti-IgE after preseasonal specific immunotherapy decreases ocular and nasal symptom scores and rescue medication use in grass pollen allergic children. Allergy 2004; 59: 973-979. (Pubitemid 39141410)
10. Rolinck-Werninghaus C, Keil T, Kopp M, Zielen S, Schauer U, von Berg A, et al,; Omalizumab Rhinitis Study Group. Specific IgE serum concentration is associated with symptom severity in children with seasonal allergic rhinitis. Allergy 2008; 63: 1339-1344.
11. Bez C, Schubert R, Kopp M, Ersfeld Y, Rosewich M, Kuehr J, et al., Effect of anti-immunoglobulin E on nasal inflammation in patients with seasonal allergic rhinoconjunctivitis. Clin Exp Allergy 2004; 34: 1079-1085. (Pubitemid 38969544)
12. Des Roches A, Paradis L, Knani J, et al., Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. V. Duration of the efficacy of immunotherapy after its cessation. Allergy 1996; 51: 430-433. (Pubitemid 26266386)
13. Durham SR, Walker SM, Varga EM, et al., Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999; 341: 468-475. (Pubitemid 29372886)
14. Moller C, Dreborg S, Ferdousi HA, et al., Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-Study). J Allergy Clin Immunol 2002; 109: 251-256. (Pubitemid 34158289)
15. Jacobsen L, Niggemann B, Dreborg S, et al., Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 2007; 62: 943-948. (Pubitemid 47037870)
16. Casale TB, Busse WW, Kline JN, Ballas ZK, Moss MH, Townley RG, et al,; Immune Tolerance Network Group. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2006; 117: 134-140. (Pubitemid 43017150)
17. Klunker S, Saggar LR, Seyfert-Margolis V, Asare AL, Casale TB, Durham SR, et al,; Immune Tolerance Network Group. Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: inhibition of IgE-facilitated allergen binding. J Allergy Clin Immunol 2007; 120: 688-695. (Pubitemid 47320761)
18. Galera C, Soohun N, Zankar N, Caimmi S, Gallen C, Demoly P,. Severe anaphylaxis to bee venom immunotherapy: efficacy of pretreatment and concurrent treatment with omalizumab. J Investig Allergol Clin Immunol 2009; 19: 225-229.
19. Kontou-Fili K, Filis CI,. Prolonged high-dose omalizumab is required to control reactions to venom immunotherapy in mastocytosis. Allergy 2009; 64: 1384-1385.
20. Kopp MV, Hamelmann E, Zielen S, Kamin W, Bergmann KC, Sieder C, et al,; DUAL Study Group. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma. Clin Exp Allergy 2009; 39: 271-279.
21. Massanari M, Nelson H, Casale T, Busse W, Kianifard F, Geba GP, et al., Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma. J Allergy Clin Immunol 2010; 125: 383-389.
22. Gawchik SM, Saccar CL,. Pollinex Quattro Tree: allergy vaccine. Expert Opin Biol Ther 2009; 9: 377-382.
23. Jain VV, Kitagaki K, Kline JN,. CpG DNA and immunotherapy of allergic airway diseases. Clin Exp Allergy 2003; 33: 1330-1335. (Pubitemid 37289926)
24. Rover AC, Reimann S, Zuberbier T, Worm M,. Immunophenotypic characterization of peripheral B cells. During short-term immunotherapy with tree pollen allergoid and the immunoadjuvant monophosphoryl lipid A. J Investig Allergol Clin Immunol 2002; 12: 227-234. (Pubitemid 36713144)
25. Drachenberg KJ, Wheeler AW, Stuebner P, Horak F,. A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy 2001; 56: 498-505. (Pubitemid 32521429)
26. Drachenberg KJ, Proll S, Urban E, Woroniecki SR,. Single-course specific immunotherapy with mixed pollen allergoids: results of a multi-centre study. Allergol Immunopathol 2003; 31: 77-82. (Pubitemid 36547193)
27. Drachenberg KJ, Heinzkill M, Urban E, Woroniecki SR,. Efficacy and tolerability of short-term specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A (MPL) for children and adolescents. Allergol Immunopathol 2003; 31: 270-277. (Pubitemid 37429027)
28. Creticos PS, Schroeder JT, Hamilton RG, Balcer-Whaley SL, Khattignavong AP, Lindblad R, et al,; Immune Tolerance Network Group. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 2006; 355: 1445-1455. (Pubitemid 44511559)
29. Dynavax Reports Interim TOLAMBA Ragweed Allergy Results from DARTT Trial [press release January 8, 2007]. Berkeley, CA: Dynavax Technologies, 2007.
30. Senti G, Johansen P, Haug S, Bull C, Gottschaller C, Muller P, et al., Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/II a clinical trial. Clin Exp Allergy 2009; 39: 562-570.
31. Kamin W, Kopp MV, Erdnuess F, Schauer U, Zielen S, Wahn U,. Safety of anti-IgE treatment with omalizumab in children with seasonal allergic rhinitis undergoing specific immunotherapy simultaneously. Pediatr Allergy Immunol 2010; 21: e160-e165.
32. Casale TB, Stokes JR,. Future forms of immunotherapy. J Allergy Clin Immunol 2011; 127: 8-15.